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Human protein C concentrate 
in pediatric septic patients
ABSTRACT
Severe sepsis and septic shock are leading causes of morbidity and mortality in the pediatric population. Unlike what is 
suggested for the adult population, recombinant human activated protein C (rhAPC) is contraindicated in children. Long 
before rhAPC was considered for use in pediatric patients, case reports appeared on the safe administration of protein C 
zymogen. Therefore, we conducted a systemic review of currently available data on protein C zymogen (PC) use among 
children affected by severe sepsis or septic shock. 
A total number of 13 case series or case reports and a dose-finding study were found on the use of  PC in the pediatric 
intensive care unit, reporting on 118 treated children, with an overall survival of 84%. There was no bleeding complication, 
the only reported complication being a single mild allergic reaction.
These studies show that PC is safe, not associated with bleeding and possibly useful for improving  coagulation abnormali-
ties of sepsis.
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Severe sepsis and septic shock are 
leading causes of morbidity and mor-
tality in the pediatric population. A large 
epidemiological study estimated 0.56 
cases per 1000 children, or 42,364 
cases per year in the United States. 
(1) Infants have the highest incidence 
(5.16 per 1,000) and sepsis is the 4th 
cause of death; children are less affec-
ted (5.16 vs 0.20 per 1000), but sepsis 
is the 2nd cause of death in this age 
group. The overall hospital mortality 
rate in this study was 10.3%. (2)
In Italy, sepsis, severe sepsis and sep-
tic shock represent 7.9%, 1.6% and 
2.1% of pediatric intensive care unit 
(PICU) admissions. Mortality for septic 
shock is 62.5%. (3) Sepsis in the pedia-
tric population is a major challenge and 
an area of paramount importance. The 
Surviving Sepsis Campaign guidelines 
of 2004 and 2008 includes a section 
named “pediatric consideration”. (4) 
Unlike what is suggested for the adult 
population, recombinant human acti-
vated protein C (rhAPC) is contrain-
dicated in children with a moderate 
evidence level.
Given the beneficial effects of rhAPC 
in adult septic patients, although much 
controversy exists on this subject, (5) a 
multicentric phase III trial was underta-
ken to assess rhAPC effectiveness in 
pediatric patients, the RESOLVE study. 
(6) That trial was stopped prematurely 
for futility: 477 patients were randomi-
zed to receive either rhAPC or placebo. 
There was no difference in the primary 
endpoint, Composite Time to Complete 
Organ Failure Resolution (CTCOFR) 
and in the secondary endpoints, i.e., 
28-day mortality and major amputa-
tions. There were numerically more 
(although not statistically significant) 
central nervous system (CNS) bleeding 
events in the rhAPC group during infu-
sion (5 vs 1, p=0.10) and the 28-day 
period (11 vs 5, p=0.13). There were 
signicantly more study-drug-related 
serious adverse events and serious 
bleeding events during the infusion and 
28-day periods in the rhAPC group. 
Long before rhAPC was considered for 
use in pediatric patients, case reports 
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appeared on the safe administration 
of protein C zymogen (PC) in septic 
children with congenital or acquired PC 
deficiency. (7) 
In our paper, we conducted a systemic 
review of currently available data on PC 
use in the literature, updated to January 
2009.
Protein C and synonymous terms were 
used to search the literature using dif-
ferent Medical Databases (PubMed, 
Embase, Google Scholar) and the 
’snowballing’ technique was applied. 
Experts in this field were also contacted 
to retrieve further published papers on 
PC. No language restriction was appli-
ed. Papers were included in this review 
if at least one patient less than 18 years 
of age was treated with PC. 
A total number of 13 case reports (7-19) 
and a dose-finding study (20) were 
found on the use of PC in the PICU, as 
shown in table 1. In 118 treated chil-
dren, the only complication reported 
was a mild allergic reaction (11) and no 
bleeding complications occurred. 
The first study was published by Ger-
son et al. in 1993 (7) and reported on a 
case of purpura fulminans in a 13-year-
old boy. The patient was administered 
PC in addition to fresh frozen plasma, 
to avoid fluid overload and to restore 
plasma PC activity that was markedly 
reduced at baseline (20-50%), to an 
arbitrary level >100% (100-200%). The 
child eventually survived, though he 
required amputation of 3 toes and sur-
gical debridement of pelvic osteone-
crosis. No complications were reported 
during or after PC use.
In 1995 Rivard et al. (8) described 4 
cases of meningococcal purpura fulmi-
nans treated with PC (age 3 months-15 
years). All patients survived. They obtai-
ned normalization of PC plasma activity, 
increase of fibrinogen and decrease of 
D-dimer levels, data implying activation 
of PC to activated PC. Two patients, who 
were treated at a relatively later stage 
than the other two, required amputati-
ons, leading the authors to speculate 
in favor of prompt administration of the 
drug, when needed. Again, no adverse 
effects were observed. Patients recei-
ved 100 units/kg body weight infused 
over 15-20 minutes, every 6-8 hours. 
This was continued until skin lesions 
ceased to develop and/or coagulation 
tests were stable. 
Smith et al. in 1997 (9) reported obser-
ved and expected mortality in 12 pati-
ents with meningococcal purpura ful-
minans. No patient died, in spite of an 
expected mortality from the Glasgow 
meningococcal septicaemia progno-
stic score (21) and the pediatric risk of 
mortality score of 80% and 57%, res-
pectively. PC was administered within 
18 hours of admission in 10 out of 12 
patients. No one experienced adver-
se reactions to the drug. Two children 
required amputations, of whom one 
had a thrombotic cerebrovascular acci-
dent with complete recovery. Unfractio-
nated heparin was used in 11 patients 
and antithrombin in one.
Ettingshausen et al. in 1999 (10) treated 
8 patients with meningococcal purpura 
fulminans who had severe acquired 
PC deficiency on hospital admission. 
Improvement or even normalization 
of global hemostatic parameters was 
achieved in all patients. Markedly ele-
vated plasminogen activator inhibitor 
- 1 (PAI-1) levels prior to treatment, 
reflecting a reduced fibrinolytic poten-
tial, decreased rapidly under PC sub-
stitution. Concomitantly, improving 
signs of purpura fulminans reflected by 
decreasing size of skin lesions, demon-
strated a restoring microcirculation. 
Six of the eight patients survived. One 
patient required limb amputation; two 
patients, with severly diminished PC 
levels at admission, died because of 
multiorgan failure. No adverse effects 
were observed with the PC concentrate 
administration.
In a case described by Clarke et al. in 
2000, (11) the authors observed nor-
malization of prothrombin time within 3 
days from the first dose of PC, reduc-
tion of activated partial thrombopla-
stin time to slightly supranormal levels 
and reduction of fibrinogen to normal 
values. The child received 100 units/kg 
body weight, intravenously, eight-hour-
ly in addition to fresh frozen plasma 300 
mL every 8-12 hours. His recovery was 
surprisingly rapid and without sequ-
elae. At the second administration of 
PC, the patients experienced a blotchy, 
transient erythematous rash without 
associated cardiovascular instability. 
To the best of our knowledge, this is 
the only side effect reported and asso-
ciated with PC use in children or adults, 
among all the available published lite-
rature. 
In 2003, the only randomized controlled 
trial on PC use among the pediatric 
population was published by de Klein. 
(20) That was a well designed, phase 
2, dose finding study in meningococcal 
septic shock. Children were randomi-
zed to receive 0, 200, 400 or 600 IU/kg/
day PC in a 4 times-a-day schedule. As 
alredy noted by other authors, activa-
tion of PC to activated PC (APC) was 
achieved. That result was significantly 
faster with increasing dosages of PC 
concentrate. The study was not adequ-
ately powered to detect a difference in 
mortality as an outcome. Nonetheless, 
expected mortality (from PRISM score) 
was higher than actual mortality (40 
vs 23%) in the treatment (all dosage) 
group. De Kleijn et al. demonstrated 
also that PC concentration in blood 
is dependent on the zymogen dose 
administered, that supplementation 
in a 4-shots-a-day schedule rose and 
maintained increased concentrations 
between doses. Importantly, authors 
showed that with a 200 IU/Kg/day, PC 
concentrations were restored to normal 
value, higher doses raising them to 
supra-normal levels. De Kleijn demon-
strated also that PC is effectively acti-
vated after administration, and that also 
activation is dose-dependent.
In 2003 Fourrier et al. (14) examined the 
pharmacokinetic properties of combi-
ned PC and antithrombin (AT) supple-
mentation in severe purpura fulminans, 
to find substantial correction of both 
values in the patients’ plasma, that pea-
ked at 18 and 48 hours after drug admi-
nistration, respectively. They used 100 
IU/kg AT as a starting bolus and 100-
150 IU/kg/day for 4 days, and 100 IU/
kg PC concentrate as a starting bolus 
plus 100 IU/kg/day in adults and 100 
IU/kg every 6 hours in children. AT and 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































respectively, were significantly higher 
in survivors than in non-survivors. They 
estimated an apparent half-life of clea-
rance from plasma of 16 hours for AT 
and 6 hours for PC. According to these 
observations, they hypothesized that, 
in order to correct AT and PC plasma 
concentrations, regimens of 200 IU/kg 
loading dose plus 150 IU/kg/day, and 
250 IU/kg loading dose plus 200 IU/
kg/day are to be reached, respective-
ly. The mortality rate in that study was 
60%, mainly due to refractory shock.
In 2004 Pettenazzo et al. (15) published 
their experience in managing 8 pediatric 
patients (aged 1 month-7 years) with 
acquired PC deficiency. PC concen-
trate was administered as a 100 IU/kg 
loading dose plus 80-100 IU/kg every 
6-12 hours depending on the plasma 
levels they achieved. They reported a 
75% survival rate with prompt response 
to therapeutic efforts. Two patients died 
of Enterovirus myocarditis and acute 
myeloblastic leukemia; blood cultures 
yielded P. aeruginosa in both cases. 
No drug-related adverse events were 
reported.
In 2005 Silvani et al. (16) retrospecti-
vely examined data from 29 patients 
from 3 PICUs during one year. 11 (38%) 
patients received PC concentrate and 
experienced improvement in plasma 
PC activity, prothrombin time (PT), 
partial thromboplastin time (PTT) and 
fibrinogen, with a favourable, although 
nonsignificant, trend toward normaliza-
tion of D-dimer, AT and platelet counts. 
Mean dose was 324 IU/kg/day (range 
66-400). No difference in mortality was 
evident between treated and untrea-
ted patients. Again, no drug-related 
adverse event was seen. Notably, in 
this paper, just 4 of 11 treated patients 
were affected by N meningitidis, whe-
reas, the other 5 were affected by other 
pathogens. In 2 cases the pathogen 
was unknown. 
In 2008, De Carolis et al. (17) reported 
a case of severe sepsis in a 28-day pre-
mature neonate with grade II intraventri-
cular hemorrhage, caused by Serratia 
marcescens, successfully treated with 
PC concentrate (100 IU/kg plus 50 IU/
kg every 6 hours for 4 days). Twenty-
four hours after drug administration 
the baby’s condition promptly impro-
ved, with rapid (48 hours) weaning from 
dopamine, rapid resolution of acute 
renal failure, and extubation by day 7. 
Skin lesions slowly improved during PC 
use. No evidence of bleeding or wor-
sening of intraventricular hemorrhage, 
as assessed by transcranial doppler 
ultrasound, was reported.
Initial reports on adult patients receiving 
PC concentrate recently appeared in 
the  literature. (22, 23) 
In infection, the inflammatory media-
tors released by the immune system 
cells upon pathogen recognition induce 
endothelial cell expression of procoa-
gulant and anti-fibrinolytic molecules, 
such as tissue factor and plasminogen 
activator inhibitor (PAI)-1. (24) This is 
aimed at preventing pathogen spread 
beyond the infectious focus through 
the systemic circulation by means of 
microvascular occlusion by thrombo-
sis, and inhibition of clot lysis by ham-
pering plasmin generation. This local 
response is profoundly deranged in 
sepsis, where an overwhelming immu-
ne response to the pathogen(s) leads 
to a massive systemic release of cyto-
kines such as interleukin (IL)-1b, IL-6, 
and tumor necrosis factor (TNF)-a. 
(25) These, in turn, induce endothelial 
recruitment to a proinflammatory and 
procoagulant state on a systemic scale. 
(26) Thus, thrombus formation occurs 
as a widespread process all over the 
microcirculation, potentially resulting in 
disseminated intravascular coagulation 
(DIC), with ensuing bleeding due to 
consumptive coagulopathy. This pro-
cess is key to organ damage, in addi-
tion to systemic hypoperfusion due to 
refractory vasodilation and decreased 
cardiac contractility.
Thrombin generation by the procoagu-
lant endothelium effectively enhances 
inflammation by cleavage of protease-
activated receptor (PAR)-1 and induc-
tion of downstream gene expression 
through NF-kB (nuclear factor – kap-
paB). Thereby, the procoagulant and 
proinflammatory responses intertwine 
and promote each other in a self-per-
petuating vicious circle. (27) The PC 
pathway has emerged as an intriguing 
and effective target of therapy, in that 
it directly acts as a natural anticoagu-
lant and profibrinolytic by preventing 
and reversing microvascular thrombus 
formation, and as an anti-inflammatory 
and cytoprotective mediator, throu-
gh interaction with membrane-bound 
PAR-1. Recently, also a relashionship 
of PC pathway and strict glicemic con-
trol has been supposed. (28, 29)
PC is a vitamin K-dependent plasma 
protein that circulates in its inactive 
(zymogen) form and is readily conver-
ted to APC by thrombin upon binding 
to thrombomodulin, a transmembra-
ne protein. Thrombin:thrombomodulin 
complex cleaves endothelial PC recep-
tor (EPCR)-bound PC to its active form. 
APC, a serine protease, inactivates coa-
gulation factors VIIIa and Va, thereby 
preventing assembly of the tenase and 
prothrombinase complexes, respective-
ly, and thus blocks the coagulation cas-
cade. On the other hand, APC cleaves 
PAR-1 (in a different site than thrombin) 
so as to convey endothelial and immu-
ne system cells anti-inflammatory and 
cytoprotective signals. (30) Moreover, 
the protein C pathway attenuates the 
neutrophil chemotactic response to pro-
inflammatory cytokines. (31)
Generation of APC does not seem to be 
the only mechanism involved in the PC 
pathway: in vitro studies have shown 
that EPCR-bound zymogen PC induces 
PAR-1 cleavage by thrombin so as to 
generate an anti-inflammatory signal. 
Therefore, EPCR appeared to switch 
the signaling specificity of thrombin 
from a cytotoxic and proinflammatory 
to a protective effect in cultured endot-
helial cells. (32) This seems to agree 
with animal studies that show reduced 
mortality from lipopolysaccharide (LPS) 
induced endotoxemia and enhanced 
survival in experimental models of peri-
toneal sepsis by means of a recombi-
nant APC variant with intact signalling 
properties on PAR-1, but < 10% anti-
coagulant activity. This might allow use 
of higher doses of those APC variants, 
with beneficial effects on inflammation 
and markedly reduced hemorrhagic 
risk. (33, 34)
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Such observations would suggest that 
PC/APC anticoagulant and anti-inflam-
matory activities are distinct, at least in 
vitro and in animal models of sepsis. 
The extent to which this is true in clinical 
practice is unknown. However, it seems 
reasonable that some anticoagulant 
and profibrinolytic activity is useful to 
promote microvascular clot lysis and 
organ reperfusion.
PC levels reach the lower limit of nor-
mal adult levels (60-70%) around 6-12 
months of age, (35) thereby increasing 
the risk of coagulopathy in the pedi-
atric septic population. Moreover, in 
some studies involving adults, defici-
ency of PC caused by consumptive 
coagulopathy is more marked than 
deficiency of other hemostatic factors, 
such as antithrombin. According to 
many recent studies, protein C levels 
are frequently decreased in sepsis, 
probably due to increased conversion 
to APC, whose short plasma half-live 
(20 minutes in vivo) induces depleti-
on of its precursor levels in the attempt 
to achieve sustained plasma activities; 
decreased liver synthesis; degradation 
by neutrophil elastases; and formation 
of EPCR:APC complexes. Protein C 
levels inversely correlate with morbi-
dity and mortality outcome of septic 
patients, regardless of age, infecting 
microorganisms, presence of shock, 
DIC, degree of hypercoagulation, or 
severity of illness. (36)
Taken together, these considerations 
suggest a strong correlation between 
PC pathway and survival from severe 
sepsis/septic shock, and reinforce the 
rationale for the attempts to norma-
lize plasma activity of PC to improve 
survival, hamper coagulopathy, and 
modulate inflammation.
One of the limitations to PC use both 
in pediatric and adult septic patients 
comes from a study by Faust et al. 
(37) who collected skin biopsies from 
patients with meningococcal purpura 
fulminans and found, within areas of 
intact endothelium, reduced immuno-
histochemical staining for EPCR and 
thrombomodulin, thus suggesting 
reduced ability of the septic endothe-
lium to activate PC to APC. Some con-
siderations, however, should be made: 
1) immunohistochemistry might not be 
the most suitable method for assess-
ing membrane expression of surface 
proteins, since oxygen radicals and 
elastases produced by immune sys-
tem cells damage those moluceles and 
induce conformational changes that 
can prevent their binding to the stains; 
2) APC levels in the plasma were not 
measured, so no definitive demonstra-
tion of impaired activation of PC in sep-
sis was provided.
On the contrary, a more recent study by 
Liaw et al. (38) showed significant vari-
ability in their capacity to activate PC 
among adult septic patients, as reflect-
ed by different baseline plasma APC 
values. Upon hospital admission, APC 
was measured in the plasma of 32 sep-
tic patients by means of a monoclonal 
antibody specifically binding APC and 
not PC. APC levels were associated 
with the outcome: survivors had signifi-
cantly higher APC values than nonsur-
vivors, although overlap exists between 
the two groups, indicating that other 
pathways beside PC may be involved 
in influencing survival from the sepsis 
syndrome. APC, however, is generated 
on demand where required, in sites of 
major thrombin activation. APC could 
be produced where and when needed, 
exert its protective effects on inflam-
mation and coagulation, and then be 
rapidly consumed in this process. It is 
unlikely that undetectable plasma lev-
els reflect the inappropriateness of our 
measurement techniques to explore 
what actually happens in the microcir-
culation. In fact, Liaw et al. showed that 
the monoclonal antibody deployed for 
such scope can detect both therapeutic 
(i.e., following administration of rhAPC) 
and physiologic (i.e., endogenous) 
concentrations of APC within 1.5 to 19 
hours, inversely depending on plasma 
APC levels. 
If the distinct existence of two groups of 
septic patients were to be validated on 
a larger scale, they could indicate that 
patient having endothelial dysfunction, 
as appears from impaired ability to gen-
erate APC, are at higher risk of death. 
Baseline plasma APC activity, beside 
PC levels, as previously reported, might 
be inversely related to survival. More-
over, identification of an “activator” 
versus “non-activator” phenotype in 
relation to the ability to generate APC 
might indicate the best treatment option 
for the patient: “activators” might ben-
efit from PCz administration, whereas 
“non-activators” should perhaps be 
administered rhAPC.
Still another aspect may be taken into 
account: in the already cited study by 
Bae et al. (32) a complementary mech-
anism of PAR-1 recruitment by PC to an 
antiapoptotic, anti-inflammatory, and 
cytoprotective signalling is described. 
It appears that, at least in vitro, the 
protective effects of PAR-1 are medi-
ated by EPCR binding by either APC or 
PC zymogen, thus suggesting that the 
anti-inflammatory properties of the PC 
pathway may not necessarily require 
APC formation. 
Conclusion
Evidence has accumulated on the 
clinical relevance of the PC pathway 
in modulating  overwhelming inflam-
mation and preventing coagulation 
derangements, two key mediators of 
organ damage, and thus of mortality 
and morbidity, in sepsis.
The RESOLVE trial (6) on the use of 
rhAPC in septic children has yielded 
negative results, indicating that rhAPC 
is of no benefit in the pediatric popu-
lation and is indeed associated with 
increased serious adverse events and 
bleeding complications.
On the contrary, PC use has long been 
attempted in sepsis-induced coagul-
opathy, especially in the context of pur-
pura fulminans, and an improvement of 
coagulation parameters and of survival 
has been described in case reports. 
Its use was sometimes reported to 
be associated with improved survival 
compared to expected figures extrapo-
lated from validated indices. To date, 
no serious adverse event related to PC 
use was described, except for a mild, 
transient cutaneous allergic reaction in 
a 17-year-old male. (11)
The experience collected through these 
studies shows that PC is safe, in that it is 
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not associated with bleeding or severe 
allergic complications, and possibly 
useful, at least to improve the coagula-
tion abnormalities brought about by 
sepsis. Unfortunately, however, all we 
know comes from case series or case 
reports or an underpowered random-
ized controlled study. A randomized 
clinical trial, adequatly powered for 
mortality or clinically relevant outcome, 
is necessary to confirm PC efficacy in 
the pediatric population.
REFERENCES
1. Watson RS, Carcillo JA. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med 2005;6:3-5.
2. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United 
States. Am J Respir Crit Care Med 2003; 167:695-701.
3. Wolfler A, Silvani P, Musicco M, Antonelli M, Salvo I. (Italian Pediatric Sepsis Study (SISPe) group) Incidence of and mortality due to 
sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: a prospective national survey . Intensive Care Med 
2008;34:1690-7. 
4. Dellinger R, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. For the International Surviving Sepsis Campaign Guidelines 
Committee Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 
2008;36:296-327.
5. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, et al. Design, conduct, analysis and reporting of a multi-national 
placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008;34:1935-47.
6. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, et al. REsearching severe Sepsis and Organ dysfunction in children: a 
gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised 
controlled trial. Lancet 2007;369:836–43. 
7. Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated 
intravascular coagulation: treatment with protein C concentrate. Pediatrics 1993;91:418-22.
8. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 
1995;126:646-52. 
9. Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in 
meningococcus-induced purpura fulminans. Lancet 1997;29:1590-3. 
10. Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jäger G, Kreuz W. Replacement therapy with protein C concentrate in infants and 
adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 1999;25:537-41.
11. Clarke RC, Johnston JR, Mayne EE. Meningococcal septicaemia: treatment with protein C concentrate. Intensive Care Med 
2000;26:471-3. 
12. Leclerc F, Cremer R, Leteurtre S, Martinot A, Fourier C. Protein C concentrate and recombinant tissue plasminogen activator in meningo-
coccal septic shock. Crit Care Med 2000;28:1694-7. 
13. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with 
protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000;96:3719-24. 
 14. Fourrier F, Leclerc F, Aidan K, Sadik A, Jourdain M, Tournoys A, et al. Combined antithrombin and protein C supplementation in menin-
gococcal purpura fulminans: a pharmacokinetic study. Intensive Care Med 2003;29:1081-7.
15. Pettenazzo A, Malusa T. Use of protein C concentrate in critical conditions: clinical experience in pediatric patients with sepsis. Minerva 
Anestesiol 2004;70:357-63. 
16. Silvani P, Camporesi A, Licari E, Wolfler A. Use of protein C concentrate in pediatric patients with sepsis. Minerva Anestesiol 
2005;71:373-8. 
17. De Carolis MP, Polimeni V, Papacci P, Lacerenza S, Romagnoli C. Severe sepsis in a premature neonate: protein C replacement therapy. 
Turk J Pediatr 2008;50:405-8.
18. Makris PE, Girtovitis F, Papadopoulos A, Tamioulaki A. Treatment of DIC: the role of PC. J Thromb Haemost 2003;1S1:P0600.
 19. Schellongowski P, Bauer E, Holzinger U,  Staudinger T, Frass M, Laczika K, et al. Treatment of adult patients with sepsis-induced coagu-
lopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin®). Vox Sanguinis 2006;90:294-301.
 20. de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, Joosten KF, et al. Activation of protein C following infusion of protein 
C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, 
dose-finding study. Crit Care Med 2003;31:1839-47. 
21. Evans SF, Johnson P, Garewal DS, Khan ZP. Glasgow meningococcal septicaemia prognostic score. Crit Care Med 1992;20:439.
22. Landoni G, Crivellari M, Monti G, Gerli C. Human protein C concentrates in adult septic patients. Signa Vitae 2008;3:12-16,301.
19www.signavitae.com
23. Crivellari M, Della Valle P, Landoni G, Pappalardo F, Gerli C, Bignami E, et al. Human protein C zymogen concentrate in patients with severe 
sepsis and multiple organ failure after adult cardiac surgery. Intensive Care Med 2009 Aug 1. [Epub ahead of print]
24. Russell JA. Management of sepsis. N Engl J Med 2006;355:1699-713.
25. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885-91.
26. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004; 47:305–14.
27. Bae JS, Yang L, Rezaie AR. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts 
of endothelial cells. Proc Natl Acad Sci U S A 2007;104:2867-72.
28. Polli F, Savioli M, Cugno M, Taccone P, Bellani G, Spanu P, et al. Effects of recombinant human activated protein C on the fibrinolytic 
system of patients undergoing conventional or tight glycemic control. Minerva Anestesiol 2009;75:417-26.
29. Schultz MJ, Levi M. Recombinant human activated protein C and strict glycemic control in sepsis: mutually exclusive strategies? Minerva 
Anestesiol 2009;75:415-6.  
30. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001;29:S69-74.
31. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 
2001;29:S48-51.
32. Bae JS, Rezaie AR. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells 
if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 2008;100:101-9. 
33. Weiler H, Ruf W. Activated protein C in sepsis: the promise of nonanticoagulant activated protein C. Curr Opin Hematol 2008;15:487-93.
34. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, et al. Endotoxemia and sepsis mortality reduction by non-antico-
agulant activated protein C. J Exp Med 2007;204:2439-48. 
35. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 
1990;12:95-104.
36. Fisher CJ Jr, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000;28:S49-56.
37. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe 
meningococcal sepsis. N Engl J Med 2001;345:408-16. 
38. Liaw PC, Esmon CT, Kahnamoui K, Schmidt S, Kahnamoui S, Ferrell G, et al. Patients with severe sepsis vary markedly in their ability to 
generate activated protein C. Blood 2004;104:3958-64. 
